// App-Quantinova.ai

e18581 : Recurrence risk in early breast cancer as defined by clinicopathologic features.

Researchers

Presenter

  • Kristin M. Sheffield

Principal Investigators

  • Jessica R. Peachey

  • Michael W. Method

  • Brenda R. Grimes

  • Jacqueline Brown

  • Kim R. Saverno

  • Yajun Emily Zhu

  • Kimberley T Lee

Medical Centers

  • Eli Lilly and Company, Indianapolis, IN

  • Eli Lilly, Indianapolis, IN

  • Eli Lilly and Company, Windlesham, United Kingdom

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

Locations

  • United States

  • United Kingdom

Companies

  • Eli Lilly and Compan

  • EMB Statistical Solu

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved